在40218例启动化疗的癌症患者中验证Khorana评分预测静脉血栓栓塞症
研究利用丹麦健康登记数据纳入40218例启动化疗且无其他抗凝指征的门诊癌症患者,按Khorana评分分层并考虑死亡竞争风险估计6个月VTE累积发生率。低危(0分)、中危(1-2分)、高危(≥3分)患者6个月VTE风险分别为1.5%、2.8%、4.1%。Khorana评分能对门诊癌症患者进行VTE风险分层,但并非所有癌种均适用;绝对风险低于关键随机试验。
要点
- Khorana评分低危(0分)、中危(1-2分)、高危(≥3分)患者6个月VTE风险分别为1.5%、2.8%、4.1%。
- 指南推荐抗凝的Khorana评分≥2患者6个月VTE风险为3.6%。
- Khorana评分在肝胆癌或胰腺癌、肺癌和妇科癌症中未能进行风险分层。
核心结论
- Khorana评分能对门诊癌症患者按VTE风险进行分层,但并非所有癌种均适用。
- 绝对风险因方法学而异,但低于关键随机试验中的风险。
- 尽管使用行政登记数据识别结局存在某些局限性,但在未选择的癌症人群中实施常规一级血栓预防的绝对获益可能小于随机试验中所见。
研究设计与样本
- 利用丹麦健康登记数据识别启动化疗且无其他抗凝指征的门诊癌症患者。
- 共纳入40218例患者,按Khorana评分分层,估计6个月VTE累积发生率。
- 分析分别采用Kaplan-Meier法和累积发生率函数,考虑与不考虑死亡竞争风险,并进行整体及按癌种分层分析。
主要发现
- 40218例患者中,35.4%为低危(评分0),53.6%为中危(评分1至2),10.9%为高危(评分≥3)。
- 考虑死亡竞争风险,低危、中危、高危患者6个月VTE风险分别为1.5%(95%CI 1.3-1.7)、2.8%(95%CI 2.6-3.1)、4.1%(95%CI 3.5-4.7)。
- 指南推荐抗凝的Khorana评分≥2患者6个月VTE风险为3.6%(95%CI 3.3-3.9)。
- Kaplan-Meier分析较竞争风险分析高估发生率高达23%。
- 采用指南推荐的阈值≥2时,Khorana评分未能对肝胆癌或胰腺癌、肺癌和妇科癌症患者进行风险分层。
关键数值与推荐
- Khorana评分低危为0分,中危为1至2分,高危为≥3分。
- 指南推荐抗凝的Khorana评分阈值为≥2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 使用行政登记数据识别结局存在某些局限性。
- Khorana评分并非对所有癌种均能进行风险分层。
- 绝对风险因方法学而异,且低于关键随机试验中的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Khorana score is recommended for guiding primary venous thromboembolism (VTE) prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains debatable. Also, some previous validation studies have ignored the competing risk of death, hereby potentially overestimating VTE risk. We identified ambulatory cancer patients initiating chemotherapy without other indications for anticoagulation using Danish health registries and estimated 6-month cumulative incidence of VTE stratified by Khorana levels. Analyses were conducted with and without considering death as a competing risk using the Kaplan-Meier method vs the cumulative incidence function. Analyses were performed overall and stratified by cancer types. Of 40 218 patients, 35.4% were categorized by Khorana as low risk (score 0), 53.6% as intermediate risk (score 1 to 2), and 10.9% as high risk (score ≥3). Considering competing risk of death, the corresponding 6-month risks of VTE were 1.5% (95% confidence interval [CI], 1.3-1.7), 2.8% (95% CI, 2.6-3.1), and 4.1% (95% CI, 3.5-4.7), respectively. Among patients recommended anticoagulation by guidelines (Khorana score ≥2), the 6-month risk was 3.6% (95% CI, 3.3-3.9). Kaplan-Meier analysis overestimated incidence up to 23% compared with competing risk analyses. Using the guideline-recommended threshold of ≥2, the Khorana score did not risk-stratify patients with hepatobiliary or pancreatic cancer, lung cancer, and gynecologic cancer. In conclusion, the Khorana score was able to stratify ambulatory cancer patients according to the risk of VTE, but not for all cancer types. Absolute risks varied by methodology but were lower than in key randomized trials. Thus, although certain limitations with outcome identification using administrative registries apply, the absolute benefit of implementing routine primary thromboprophylaxis in an unselected cancer population may be smaller than seen in randomized trials.
引用
- Overvad TF, Ording AG, Nielsen PB, et al. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Adv. 2022. PMID: 35045569. doi:10.1182/bloodadvances.2021006484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。